Welcome to our dedicated page for InfuSystem Holdings SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on InfuSystem Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into InfuSystem Holdings's regulatory disclosures and financial reporting.
InfuSystem Holdings, Inc. reported a board leadership change following its 2026 Annual Meeting of Stockholders held on May 11, 2026. The newly constituted Board of Directors elected Beverly Huss to serve as Chairman of the Board of Directors.
The company states that there are no arrangements or understandings with other persons related to her appointment, no family relationships between Ms. Huss and any directors or executive officers, and no material related-party transactions involving her that require disclosure under Item 404(a) of Regulation S-K.
InfuSystem Holdings, Inc. reported results from its 2026 annual stockholder meeting and an update to its equity compensation plan. Stockholders approved a Third Amendment to the 2021 Equity Incentive Plan, increasing the maximum number of shares of common stock reserved for issuance under the plan to 7,000,000 shares. The plan allows a range of equity and cash awards for employees, consultants, and directors, administered by the Board’s Compensation Committee.
All seven Board nominees were elected, each receiving over 11.8 million votes in favor with 3.7 million broker non-votes. On a non-binding, advisory basis, stockholders approved executive compensation with about 11.9 million votes for and 1.1 million against. They also approved the equity plan amendment and ratified Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
InfuSystem Holdings director Paul Andrew Gendron bought additional company stock in the open market. On this Form 4, he reports purchasing 5,000 shares of common stock in an open-market transaction at a weighted average price of $8.88 per share, increasing his direct holdings to 70,000 shares. A footnote explains the price reflects multiple trades on the transaction date and that full trade-by-trade pricing information is available upon request.
InfuSystem Holdings, Inc. President and CEO Carrie Lachance bought a net 3,000 shares of common stock in open-market purchases. She acquired 2,000 shares at $8.83 per share on May 8, 2026 and 1,000 shares at $8.46 per share on May 11, 2026.
After these transactions, she directly holds 238,123 shares of InfuSystem common stock. This total includes an additional 2,949 shares recently acquired through the company’s Employee Stock Purchase Plan.
InfuSystem Holdings, Inc. Executive VP and CFO Barry G. Steele reported buying 7,000 shares of common stock in an open-market purchase at a weighted average price of $8.707 per share. Following this transaction, he directly holds 96,590 common shares, including 1,590 shares recently acquired through the Company’s Employee Stock Purchase Plan.
InfuSystem Holdings reported Q1 2026 net revenue of $33.7 million, down 3% from $34.7 million a year earlier, but moved to net income of $1.0 million versus a $0.3 million loss. Gross margin improved to 58.4% from 55.2% as higher-margin Patient Services outpaced softer Device Solutions.
Patient Services revenue rose 6.4% to $22.1 million, driven by oncology and fast-growing wound care, while Device Solutions fell 16.9% to $11.6 million amid lower biomedical services and prior-year rental buyout effects. Operating income more than doubled to $1.6 million. Cash was $2.1 million with $20.0 million drawn on a $75.0 million revolver and $55.0 million of remaining availability. The company continued its share repurchase program, having bought back $11.8 million of stock cumulatively.
InfuSystem Holdings reported first quarter 2026 net revenues of $33.7 million, down 3% from $34.7 million a year earlier, mainly due to a restructured GE Healthcare biomedical services contract. On a pro-forma basis, revenue grew 1.7%.
Patient Services net revenue rose 6% to $22.1 million, driven by Oncology and rapidly expanding Wound Care, while Device Solutions fell 17% to $11.6 million. Net income was $1.0 million, or $0.05 per diluted share, compared with a net loss of $0.3 million, or $0.01 per diluted share, last year.
Adjusted EBITDA was $6.4 million with an 18.9% margin, roughly flat in dollars but higher as a percentage of revenue. Liquidity totaled $57.1 million as of March 31, 2026, and the company reaffirmed full-year 2026 guidance for 6%–8% pro-forma net revenue growth and Adjusted EBITDA margins in the mid to low 20% range.
InfuSystem Holdings, Inc. announced it will release its first quarter 2026 financial results on May 7, 2026, before the market opens. On the same day, the Company will host a conference call at 9:00 a.m. Eastern Time for investors and other interested parties.
Participants can join by phone or via a live webcast in the Investors section of InfuSystem’s website, with a telephone and online replay available through May 14, 2026.
InfuSystem Holdings, Inc. is asking shareholders to approve seven director nominees, an advisory vote on executive pay, an increase to its 2021 Equity Incentive Plan share pool, and ratification of Grant Thornton as auditor at a fully virtual May 11, 2026 annual meeting.
The proxy highlights a strong 2025, with record revenue of $143.4 million, up 6%, net income of $6.6 million, up 183%, and record Adjusted EBITDA of $31.5 million with a 21.9% margin. Operating cash flow rose to $24.4 million, while capital spending fell by more than 50%, net debt dropped 30% to $16.4 million, and the company repurchased 1.3 million shares for $9.9 million.
Management describes a shift toward less capital‑intensive growth, led by rapid expansion in wound care and continued oncology strength, and notes a 2026 restructuring of its largest biomedical services contract that will reduce annual revenue by $7.1 million but is expected to improve earnings and cash flow. The board seeks to add 1,000,000 shares to the 2021 Equity Incentive Plan, bringing the reserve to 7,000,000 shares, to continue using equity awards as a key part of executive and director compensation.
InfuSystem Holdings, Inc. has changed its independent auditor for the fiscal year ending December 31, 2026. After a competitive selection process, the board’s Audit Committee dismissed Deloitte & Touche LLP and appointed Grant Thornton LLP to audit the 2026 consolidated financial statements, quarterly reviews, and internal control over financial reporting.
The company states that Deloitte’s audit reports for 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications. It also reports no disagreements or reportable events with Deloitte over those years and through March 13, 2026, and says it did not previously consult Grant Thornton on accounting or audit matters. A confirming letter from Deloitte is filed as an exhibit.